Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
Top Page
Champions Oncology
(NASDAQ:CSBR)
Select Model
Select Model
Rating:53Neutral
Price Target:
$6.50
▲(1.25% Upside)
Champions Oncology's overall stock score reflects a mixed outlook. The most significant factor is the financial performance, which shows improvements in profitability but is hindered by high leverage and declining cash flow. Technical analysis indicates a bearish trend, while valuation suggests the stock is overvalued. The earnings call provides cautious optimism with potential for future growth, but current challenges remain.
Champions Oncology (CSBR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.87M
Dividend YieldN/A
Average Volume (3M)32.37K
Price to Earnings (P/E)31.5
Beta (1Y)0.36
Revenue Growth10.11%
EPS GrowthN/A
CountryUS
Employees210
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.02
Shares Outstanding13,788,421
10 Day Avg. Volume16,739
30 Day Avg. Volume32,370
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)25.89
Price to Sales (P/S)1.72
P/FCF Ratio13.96
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit5.94
Enterprise Value/Ebitda23.56
Forecast
1Y Price Target
$12.00Price Target Upside86.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Champions Oncology Business Overview & Revenue Model
Company DescriptionChampions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
How the Company Makes MoneyChampions Oncology generates revenue through its personalized oncology solutions and collaboration with pharmaceutical companies. Its key revenue streams include the sale of its proprietary TumorGraft Technology Platform, which facilitates the creation of personalized cancer treatment plans by implanting human tumors in mice for drug testing. Additionally, the company earns income from its drug discovery and development services, which include preclinical studies and clinical trials. Strategic partnerships and collaborations with major pharmaceutical companies further bolster its earnings by providing opportunities for joint research and development projects.
Champions Oncology Earnings Call Summary
Earnings Call Date:Sep 15, 2025
(Q1-2026)
| % Change Since: |
Next Earnings Date:Dec 16, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a company in transition, showing signs of recovery with revenue rebounding from Q4 and strong momentum in its data platform and radiopharmaceutical services. However, challenges remain, as evidenced by flat year-over-year revenue, an operating loss, and decreased gross margins. The financial position is stable with a strong cash reserve and no debt. While there are positive developments, the balance between highlights and lowlights suggests cautious optimism.Q1-2026 Updates
Positive Updates
Revenue Rebound
The company delivered $14 million in revenue for Q1, rebounding from $12.4 million in Q4, showing a return to growth and stability.
Strong Data Platform Momentum
The data platform has generated sales for three consecutive quarters, creating the most comprehensive and clinically relevant tumor data set in the industry.
Radiopharmaceutical Services Expansion
The company expanded its radiopharmaceutical services platform, which is expected to reduce costs and improve gross margins by bringing work in-house.
Cash Position and Debt-Free Status
Champions Oncology ended Q1 with $10.3 million in cash and remains debt-free, providing financial flexibility and resilience.
Negative Updates
Flat Year-over-Year Revenue
Revenue for Q1 was essentially flat compared to the first quarter of last year, indicating challenges in achieving year-over-year growth.
Operating Loss
The company recorded a loss from operations of $0.5 million compared to income from operations of $1.3 million in the same quarter last year.
Gross Margin Decline
Gross margin declined from 50% in Q1 of last year to 43% this quarter, primarily due to increased outsourced lab service costs.
Increased Operating Expenses
Operating expenses rose by $1 million compared to last year, attributed to increased R&D, sales and marketing, and G&A costs.
Company Guidance
During the Champions Oncology First Quarter Fiscal Year 2026 earnings call, CEO Rob Brainin and CFO David Miller provided insights into the company's performance and strategy. The company reported $14 million in revenue for the quarter, marking a rebound from the $12.4 million in Q4 and stabilization compared to the first quarter of the previous year. The company's TOS business led growth, with contributions from the emerging data platform. However, the gross margin declined to 43% from 50% in the previous year due to increased outsourced lab service costs. Despite a GAAP operating loss of $0.5 million, adjusted EBITDA was slightly positive at $60,000. Champions Oncology ended the quarter with $10.3 million in cash and no debt, maintaining financial flexibility. The company is optimistic about the potential of its data and Corellia businesses, with expectations for sequential revenue growth, margin expansion, and cash growth in the latter half of fiscal 2026.Champions Oncology Financial Statement Overview
Summary
Champions Oncology's financial statements depict a company facing significant challenges in revenue stability and cash management, despite some improvements in equity and net income. The high leverage and inconsistent profit margins reflect potential risks, while cash flow issues underscore liquidity concerns. Overall, the company is in a transitional phase, showing both vulnerabilities and some recovery indicators.Income Statement
The company exhibits a volatile income statement with a negative gross profit margin in TTM, indicating more costs than revenue. Despite a positive net income in TTM, the revenue growth rate is negative, showing declining sales over time. Margins are inconsistent, with significant fluctuations in EBIT and EBITDA margins. The overall income statement suggests instability in revenue generation and cost management.65
Positive
Balance Sheet
The balance sheet reveals a concerning debt-to-equity ratio, indicating high leverage. However, the TTM data shows improved stockholders' equity, suggesting a recovery trend. ROE is positive in TTM, reflecting recent profitability. The equity ratio remains low, indicating potential financial risk due to dependence on liabilities. The balance sheet points to a moderate risk profile with some signs of recovery.55
Neutral
Cash Flow
Cash flow analysis shows negative free cash flow growth in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash outflows even with positive net income. This trend suggests problems in converting earnings into cash. The cash flow statement highlights liquidity challenges and inefficiencies in cash operations.50
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.88M | 56.94M | 50.16M | 53.87M | 49.11M | 41.04M |
| Gross Profit | 13.93M | 28.55M | 20.75M | 24.34M | 25.48M | 19.57M |
| EBITDA | 3.51M | 6.49M | -5.05M | -2.07M | 2.23M | 366.00K |
| Net Income | 2.92M | 4.70M | -7.28M | -5.33M | 548.00K | 362.00K |
Balance Sheet | ||||||
| Total Assets | 30.55M | 32.34M | 26.13M | 34.31M | 35.38M | 27.59M |
| Cash, Cash Equivalents and Short-Term Investments | 10.32M | 9.79M | 2.62M | 10.12M | 9.01M | 4.69M |
| Total Debt | 5.75M | 6.11M | 7.43M | 8.60M | 9.47M | 9.60M |
| Total Liabilities | 27.01M | 28.57M | 28.04M | 29.68M | 26.28M | 20.16M |
| Stockholders Equity | 3.51M | 3.77M | -1.90M | 4.64M | 9.10M | 7.43M |
Cash Flow | ||||||
| Free Cash Flow | 7.24M | 7.00M | -6.97M | 1.08M | 4.11M | -4.96M |
| Operating Cash Flow | 7.67M | 7.39M | -6.14M | 3.96M | 6.50M | -1.68M |
| Investing Cash Flow | -435.00K | -389.00K | -836.00K | -2.87M | -2.38M | -3.17M |
| Financing Cash Flow | 193.00K | 170.00K | -527.00K | 11.00K | 207.00K | 1.20M |
Champions Oncology Technical Analysis
Negative
6.42
Price Trends
6.67
Negative
6.93
Negative
8.00
Negative
Market Momentum
-0.14
Positive
44.17
Neutral
24.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 6.42 is below the 20-day moving average (MA) of 6.62, below the 50-day MA of 6.67, and below the 200-day MA of 8.00, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 24.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Champions Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $193.75M | 32.84 | 15.99% | ― | 62.79% | ― | |
53 Neutral | $86.87M | 31.53 | 185.89% | ― | 10.11% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $106.98M | ― | -57.94% | ― | ― | 11.78% | |
43 Neutral | $175.36M | ― | -88.95% | ― | ― | -553.86% | |
36 Underperform | $130.46M | ― | -41.66% | ― | ― | -8.91% |
* Healthcare Sector Average
CSBR
Champions Oncology
6.42
1.83
39.87%
SAVA
Cassava Sciences
3.57
-22.48
-86.30%
PLX
Protalix
2.60
1.58
154.90%
ATOS
Atossa Therapeutics
1.00
-0.42
-29.58%
ANIX
Anixa Biosciences
3.25
0.17
5.52%
ACTU
Actuate Therapeutics, Inc.
7.02
0.07
1.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.